All AbMole products are for research use only, cannot be used for human consumption.
AGI-5198 (also know as IDH-C35) is a potent and selective mutant IDH1 inhibitor. AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2-HG production in HT1080 and U87MG cells with IC50 values of 0.48 μM and 0.07 μM, respectively. AGI-5198 (IDH-C35) inhibits IDH1 R132H mutant and R132C mutant in vitro with IC50 of 0.07 μM and 0.16 μM respectively, but not wild-type IDH1 or any of the examined IDH2 isoforms (IC50 > 100 μM). In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts. Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.
 |
Source | Cancer Res (2015). Figure 1. AGI-5198 |
| Method | Colony-forming assays | |
| Cell Lines | IDH1MT cells | |
| Concentrations | 800 nmol/L | |
| Incubation Time | 72 h | |
| Results | After 72 hours of incubation in the presence of AGI-5198, IDH-mediated NADPH production capacity of lDH1WT/R132H HCT116 cells was restored to levels comparable with those of lDH1WT/WT HCT116 cells |
| Molecular Weight | 462.56 |
| Formula | C27H31FN4O2 |
| CAS Number | 1355326-35-0 |
| Solubility (25°C) | DMSO 15 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Isocitrate Dehydrogenase (IDH) Products |
|---|
| AGI-6780
AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM. |
| Enasidenib
Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively. |
| BAY-1436032
BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells. |
| GSK864
GSK864 is a cell penetrant, potent and selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) that potently inhibits intracellular 2-hydroxyglutarate (2-HG) production in HT-1080 cells. |
| Ivosidenib
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
